784-785 / 1578
ESMO Guidelines [Vansteenkiste J, Ann Oncol 2014]
•
“pre-treatment pathological diagnosis strongly recommended in all patients
before
any curative treatment
, unless a multidisciplinary tumour board (MDT)
is of the opinion that the risk-benefit ratio of the procedure is unacceptable.
Treatment without pathology
•
Expert MDT’s best placed to assess likelihood of benign disease in their
populations including, where available,
algorithms
validated for the
population in question. In case of the latter, a
likelihood of malignancy
exceeding 85%
may be preferred”.